Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (311-320 of 461) with videos related to

Pageof 47
Sort By:
Frontiers in Neuroinformatics|March 27, 2023
A neuroscientist's guide to using murine brain atlases for efficient analysis and transparent reportingHeidi Kleven, Ingrid Reiten, Camilla H Blixhavn, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Comprehensive Psychiatry|November 26, 1998
Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorderC M Grilo, R Money, D H Barlow, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
The Journal of Dermatology|July 18, 2017
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trialMasatoshi Abe, Chikako Nishigori, Hideshi Torii, et al.
Dermatology and Therapy|April 20, 2025
Canadian Consensus Guidelines for the Management of VitiligoVimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, et al.
The Journal of Clinical Psychiatry|December 31, 1997
Clomipramine treatment of panic disorder: pros and consL A Papp, F R Schneier, A J Fyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyKim A Papp, Thomas Werfel, Regina Fölster-Holst, et al.
Pageof 47

Showing results (311-320 of 461) with videos related to

Sort By:
Pageof 47
Frontiers in Neuroinformatics|March 27, 2023
A neuroscientist's guide to using murine brain atlases for efficient analysis and transparent reportingHeidi Kleven, Ingrid Reiten, Camilla H Blixhavn, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Comprehensive Psychiatry|November 26, 1998
Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorderC M Grilo, R Money, D H Barlow, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
The Journal of Dermatology|July 18, 2017
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trialMasatoshi Abe, Chikako Nishigori, Hideshi Torii, et al.
Dermatology and Therapy|April 20, 2025
Canadian Consensus Guidelines for the Management of VitiligoVimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, et al.
The Journal of Clinical Psychiatry|December 31, 1997
Clomipramine treatment of panic disorder: pros and consL A Papp, F R Schneier, A J Fyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyKim A Papp, Thomas Werfel, Regina Fölster-Holst, et al.
Pageof 47